Overview of lung cancer biomarkers
Lung-Carcinoma-Portal
Lung-Carcinoma-Portal
The QuIP Lung-Carcinoma-Portal is intended to serve pathologists as well as medical specialists of other disciplines and oncologists by providing orientation at the interface between biomarker tests and therapy. A biomarker-based treatment algorithm for lung cancer (NSCLC and SCLC) based on both current medical guideline recommendations and new scientific evidence has been deposited on the portal. According to the current WHO classification, NSCLC includes the following histological types: Squamous cell carcinoma (approximately 25 percent), Adenocarcinoma (approximately 42 percent), Large cell carcinoma (approximately 10 percent) and the Other and Unspecified (O & U) group.
Background
QuIP has set itself the task of accompanying pathologists in Germany and Europe in optimizing their examination results and to support them in all relevant professional and organizational activities in quality assurance.
Lung carcinomas are among the most common malignant diseases in Germany. They are the second most common cancer for men and the third most common for women. Worldwide and in Germany, lung cancer is the most common cause of cancer-related deaths and is responsible for 27 percent of cancer-related deaths overall.
According to the Center for Cancer Registry Data, approximately 21,500 women and 36,000 men developed malignancies of the lung in 2016. The five-year survival rate is about 15 percent for men and 21 percent for women, making lung cancer one of the most prognostically unfavorable cancers. The number of cancer-related deaths is about twice as high for men as for women, at 30,000/year. A shift in the histology ratio continues to be noteworthy. On the one hand, there is an increase in the proportion of small cell bronchial carcinomas, and on the other hand, among non-small cell carcinomas, the proportion of adenocarcinomas is increasing and the proportion of squamous cell carcinomas is decreasing. Currently, adenocarcinomas account for about 42 percent of lung carcinomas, about 25 percent are squamous cell carcinomas and just under 20 percent are small cell lung carcinomas.
The portal will be continuously expanded and further developed.
Data protection
Data protection in Germany prevents QuIP from publicly sharing the portal and the link to the website. Only the introduction can be seen on the portal start page, all other content is only available to medical professionals.
Registered QuIP users will automatically find a link to the Lung-Carcinoma-Portal after logging in on the QuIP homepage. All physicians who have DocCheck access will also have access to the Lung-Carcinoma-Portal. All other interested parties without a QuIP account or DocCheck access can request access to the portal by sending an e-mail to QuIP. An access code will be provided once the requestor’s access requirements are checked.
The QuIP is supported by AMGEN, AstraZeneca, Bristol Myers Squibb, Janssen-Cilag, Lilly, Merck Serono und MSD Sharp & Dohme.
